Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Stage/Subtype:  recurrent small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 33 for your search:
Start Over
SC16LD6.5 in Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SCRX16-001, NCI-2014-00483, NCT01901653
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ME-344-002, NCI-2014-01013, NCT02100007
Stereotactic Body Radiation Therapy and Radiofrequency Ablation in Treating Patients With Inoperable and Recurrent Lung Cancer Near Central Airways
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-08-026, NCI-2010-01669, 10-000656, NCT01051037
Ganetespib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-048, NCI-2010-01920, NCT01173523
Targeted Enzyme Inhibitor Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-1726, NCI-2013-00402, NCT01803269
Pegylated Irinotecan NKTR 102 in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 225612, NCI-2013-01142, NCT01876446
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, NCT01935336
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14018, NCI-2014-00808, 2013-003713-18, DRKS00007849, U1111-1154-9805, NCT02038647
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ALDOXORUBICIN-P2-SCLC-01, NCI-2014-02472, NCT02200757
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-006, NCI-2014-02188, NCT02213133
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, NCT02312622
Selinexor in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14136, NCI-2014-02489, NCT02351505
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 508-08, NCI-2009-01308, UNMC-50808, IRB #508-08, NCT00856037
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients with Locally Advanced Thoracic Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00017361, NCI-2013-01246, NCI-2010-01341, NCT00921739
Belinostat, Cisplatin, and Etoposide in Treating Patients with Recurrent or Advanced Small Cell Lung Cancer or Neuroendocrine Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0173, NCI-2013-01451, 090173, 09-25-0099, NCI 8238, P09511, P8238_A22PAMDREVW01, 8238, NCT00926640
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200858, NCI-2014-00693, NCT02034123
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VX12-970-001, NCI-2014-02042, 2012-003126-25, NCT02157792
Start Over